Equities research analysts predict that Voyager Therapeutics (NASDAQ:VYGR) will report earnings of ($0.57) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Voyager Therapeutics’ earnings, with estimates ranging from ($0.77) to ($0.44). Voyager Therapeutics reported earnings of ($0.65) per share during the same quarter last year, which would indicate a positive year over year growth rate of 12.3%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, May 8th.

According to Zacks, analysts expect that Voyager Therapeutics will report full year earnings of ($2.54) per share for the current fiscal year, with EPS estimates ranging from ($3.36) to ($1.20). For the next financial year, analysts forecast that the company will report earnings of ($3.28) per share, with EPS estimates ranging from ($4.70) to ($2.61). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Voyager Therapeutics.

How to Become a New Pot Stock Millionaire

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.32. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. The firm had revenue of $6.35 million for the quarter, compared to analysts’ expectations of $5.81 million.

A number of research analysts have commented on the company. ValuEngine upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, January 23rd. BidaskClub cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Finally, Morgan Stanley started coverage on Voyager Therapeutics in a research note on Friday, February 2nd. They issued an “overweight” rating on the stock. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $29.73.

NASDAQ:VYGR traded down $0.23 during trading hours on Monday, reaching $18.52. 87,188 shares of the stock were exchanged, compared to its average volume of 431,002. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $31.91. The stock has a market capitalization of $603.88, a price-to-earnings ratio of -6.96 and a beta of 2.98.

In other news, insider Bernard Ravina sold 2,451 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $18.24, for a total value of $44,706.24. Following the sale, the insider now directly owns 4,902 shares in the company, valued at $89,412.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Dinah Ph.D. Sah sold 15,623 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $30.00, for a total value of $468,690.00. Following the completion of the sale, the insider now owns 140,872 shares in the company, valued at $4,226,160. The disclosure for this sale can be found here. Over the last quarter, insiders sold 66,908 shares of company stock worth $1,574,258. Insiders own 8.00% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Voyager Therapeutics by 73.9% in the fourth quarter. BlackRock Inc. now owns 1,210,763 shares of the company’s stock valued at $20,099,000 after buying an additional 514,345 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Voyager Therapeutics by 290.5% in the fourth quarter. Farallon Capital Management LLC now owns 654,812 shares of the company’s stock valued at $10,870,000 after buying an additional 487,147 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Voyager Therapeutics by 19.2% in the fourth quarter. Wells Fargo & Company MN now owns 449,525 shares of the company’s stock valued at $7,462,000 after buying an additional 72,335 shares during the last quarter. AXA purchased a new position in Voyager Therapeutics in the fourth quarter valued at $5,591,000. Finally, Millennium Management LLC purchased a new position in Voyager Therapeutics in the fourth quarter valued at $4,579,000. 78.22% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2018/04/16/voyager-therapeutics-vygr-expected-to-post-earnings-of-0-57-per-share.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.